Metropolis Healthcare has announced a Q1FY27 earnings conference call to discuss its financial results for the quarter ended June 30, 2026. The call is organized by JM Financial Institutional Securities Limited and is scheduled for Wednesday, August 5, 2026, at 09:00 AM IST. The announcement was made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Conference Call Details

The earnings call will be accessible to participants across multiple geographies. The following table summarizes the scheduled timings across key time zones:

*Indicates the place/city is observing daylight saving time (DST) at the time shown.

Company Participants

The following senior management representatives of Metropolis Healthcare are scheduled to participate in the call:

• Ms. Ameera Shah — Chairperson & Whole-time Director
• Mr. Surendran Chemmenkotil — Managing Director
• Mr. Sameer Patel — Chief Financial Officer
• Mr. Mohan Menon — Chief Marketing Officer

Dial-In Information

Participants are advised to dial in 10 minutes prior to the scheduled start time to ensure timely connectivity. The following dial-in numbers are available:

For further information regarding the conference call, participants may contact JM Financial Institutional Securities Limited through the following representatives:

• Mr. Amey Chalke — +91 9664976620 | amey.chalke@jmfl.com
• Mr. Abin Benny — +91 7710066464 | abin.benny@jmfl.com
• Mr. Gourav Bhama — +91 9650984629 | gourav.bhama@jmfl.com

Regulatory Disclosure

The intimation was filed by Kamlesh C Kulkarni, Head – Legal & Secretarial, on behalf of Metropolis Healthcare, dated July 28, 2026, under reference MHL/Sec&Legal/2026-27/29. Participants are advised that management discussion and comments during the call may include forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated.

Metropolis Healthcare Limited reported robust financial results for the fiscal year ended March 31, 2026 (FY26), with consolidated revenue from operations increasing by 24% to ₹1,646 crore. Profit After Tax (PAT) surged by 31% to ₹191 crore, reflecting improved operating leverage and disciplined cost management. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) grew by 32% to ₹401 crore, expanding the EBITDA margin to 24.4% from high single digits in the prior year.

The financial strength was driven by broad-based growth across consumer and institutional segments. On an organic basis, patient volumes increased by 7.5% to 13.5 million, while test volumes grew by 8.0% to 28.4 million. Revenue per patient improved by 6%, indicating a shift towards higher-value testing. Organic Business-to-Consumer (B2C) revenue rose by 14%, and Business-to-Business (B2B) revenue increased by 13%. Specialty Diagnostics and TruHealth segments recorded organic growth of 16% and 21%, respectively, reinforcing the company's premiumisation strategy.

Key Financial Metrics

Operational expansion played a critical role in the year's performance. Metropolis added approximately 490 service centres, bringing its total network to over 5,000 touchpoints across more than 750 towns. The company successfully integrated four acquisitions during the year: Core Diagnostics, Scientific Pathology, Dr Ahujas’ Pathology and Imaging Centre (DAPIC), and Ambika Pathology. These acquired businesses contributed approximately 8% of Group revenue and increased North India's share of the business from 8% to 17%. Core Diagnostics emerged as a strategic platform for oncology and genomics, exiting the year with high single-digit EBITDA margins.

Strategic Developments and Shareholder Returns

In March 2026, the company issued bonus shares in a 3:1 ratio, capitalising approximately ₹31.10 crore from the securities premium account to enhance liquidity and broaden the shareholder base. The Board declared first and second interim dividends of ₹4 and ₹1 per equity share, respectively, for FY26. No final dividend was recommended.

The company also transferred its External Quality Assessment Services (EQAS) business to its wholly-owned subsidiary, Metropolis Quality Solutions Private Limited, for a consideration of up to ₹1.25 crore. This restructuring aims to enable the EQAS business to operate as an independent unit with dedicated management resources.

What the Numbers Show

The divergence between reported PAT growth (31%) and the previous year's normalised figures highlights the impact of one-off expenses in FY25. The prior year included approximately ₹21 crore in acquisition-related costs and legal fees, which suppressed comparables. Excluding these items, the underlying operational improvement is evident in the EBITDA margin expansion to 24.4%. Furthermore, the significant contribution from recently acquired entities (8% of revenue) demonstrates the effectiveness of the company's integration playbook, where year one focuses on synergy capture. The rise in revenue per patient by 6% suggests that growth is not solely volume-driven but also benefits from a richer mix of specialty and preventive healthcare tests.